The FDA has expanded the approval of Baqsimi nasal powder to include treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.

The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.

Explore Xeris Biopharma's revenue growth, promising pipeline, & thriving products. Learn about their strong outlook & ...

Keep reading to learn how nasal sumatriptan works, who could benefit, and how it compares with other types of sumatriptan.

A nasal cleansing wash sold nationwide is being recalled because the product may be contaminated with bacteria, according to a notice posted this week by the U.S. Food and Drug Administration.

Emrosi™ (minocycline hydrochloride extended-release capsules) is now available for the treatment of inflammatory lesions (papules and pustules) of rosacea in adults. Emrosi, a tetracycline-class ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With the potential to significantly change consumer eating habits, they are ...

STS101 is an investigational dihydroergotamine (DHE) nasal powder product that is administered via a proprietary nasal delivery device. According to Satsuma Pharmaceuticals, the dry powder DHE ...

I am somewhere in the trees. Thigh-deep in powder. Stomping through the snow. Not riding my board as I should be but carrying it. Muttering to myself about taking the wrong line and getting stuck ...